Floatz logo

Treosulfan

Childhood Myelodysplastic Syndromes

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Childhood Myelodysplastic Syndromes cohort.

View all 34

Same molecule, other indications

Treosulfan is also rated in:

myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →
Lymphoblastic Leukemia, Acute, Childhood;Dormant
BB
Indicative ·
66 / 100
View asset →
acute biphenotypic leukemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →